"T Cell Regulation of Antibody Responses to Infection and Immunization" by Jennifer Shuen Chen

Date of Award

Spring 2022

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Department

Immunobiology

First Advisor

Eisenbarth, Stephanie

Abstract

T follicular helper (Tfh) cells are the conventional drivers of protective, germinal center (GC)-based antiviral antibody responses. However, loss of Tfh cells and GCs has been observed in patients with severe COVID-19. As T cell-B cell interactions and immunoglobulin class switching still occur in these patients, non-canonical pathways of antibody production may be operative during SARS-CoV-2 infection. We found that both Tfh-dependent and -independent antibodies were induced against SARS-CoV-2 infection, SARS-CoV-2 vaccination, and influenza A virus infection. Even though Tfh-independent antibodies to SARS-CoV-2 had evidence of reduced somatic hypermutation, they were still high-affinity, durable, and reactive against diverse spike-derived epitopes and were capable of neutralizing both homologous SARS-CoV-2 and the B.1.351 (beta) variant of concern. Indeed, we found by epitope mapping and BCR sequencing that Tfh cells focused the B cell response and therefore, in the absence of Tfh cells, a more diverse clonal repertoire was maintained. These data support a new paradigm for the induction of B cell responses during viral infection that enables effective, neutralizing antibody production to complement traditional GC-derived antibodies that might compensate for GCs damaged by viral inflammation.Furthermore, we sought to reconcile the roles of Tfh cell-derived IL-4 as both a pro-survival factor for highly proliferative GC B cells as well as a switch factor for IgE and IgG1. Due to its potent effects on B cell proliferation and differentiation, IL-4 is considered a canonical Tfh cell cytokine, produced even during antimicrobial responses that elicit little IgG1 and no IgE. However, given that IL-4 is also a switch factor that is sufficient for IgE induction, this raises the question of how Tfh cells produce IL-4 during type 1 immune responses without aberrantly inducing IgE. We first clarified the role of Tfh cell-derived IL-4 during type 1 immune responses, finding that it was required for IgG1 switching in response to immunization with lipopolysaccharide and haptenated protein antigen as well as influenza A virus infection; however, GC B cell formation and plasmablast differentiation were unaffected by the loss of IL-4 from Tfh cells. In addition, we found that Tfh cells during type 1 immune responses generated minimal IL-4 protein, with levels of IL-4 tightly regulated by both transcriptional and post-transcriptional mechanisms. These data support the role of Tfh cell-derived IL-4 as a rheostat for the appropriate induction of IgG1 versus IgE antibodies during type 1 and type 2 immune responses, rather than as a pro-survival factor for GC B cells. Finally, when public health officials raised concerns about the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for treating COVID-19 at the start of the pandemic, we sought to determine whether and how NSAIDs could affect COVID-19 pathogenesis. NSAIDs affect the production of prostaglandins, which play diverse biological roles in homeostasis and inflammatory responses. Thus, it is plausible that NSAIDs could affect COVID-19 pathogenesis in multiple ways, including modifying expression of angiotensin-converting enzyme 2 (ACE2), the cell entry receptor for SARS-CoV-2; regulating replication of SARS-CoV-2 in host cells; and modulating the immune response to SARS-CoV-2. We found that NSAID treatment had no effect on ACE2 expression, viral entry, or viral replication. However, NSAIDs did affect the immune response to SARS-CoV-2 by impairing the production of proinflammatory cytokines as well as early neutralizing antibodies. Our findings therefore indicate that NSAID treatment may affect COVID-19 outcomes by dampening the inflammatory response and the production of protective antibodies, which also has implications for NSAID use during SARS-CoV-2 vaccination.

Share

COinS